drugset
drugset / Trial / NCT02659098

A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy

NCT02659098 ↗

Phase 2 Completed 21 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and performance profile of the suprachoroidal surgical approach and the Delivery System.

Timeline

Start
2015-12-04
Primary completion
2019-06-05
Completion
2019-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject CNTO 2476 Cell therapy 300000 cells Other

Indications

age-related macular degeneration diffuse secondary choroid atrophy